Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay

Matti S. Aapro, David S Alberts, Sydney E. Salmon

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Purified human leukocyte interferon produced by recombinant techniques (IFN-αA) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-αA. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-αA and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-αA is due to some of their common mechanisms of action.

Original languageEnglish (US)
Pages (from-to)161-166
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume10
Issue number3
DOIs
StatePublished - 1983

Fingerprint

Vinca Alkaloids
Interferon-alpha
Tumors
Assays
Cells
Etoposide
Tumor Cell Line
Vindesine
Neoplasms
Melphalan
Vinblastine
Vincristine
Platinum
Pharmaceutical Preparations
Doxorubicin
Cisplatin
Agar
Colon
Breast
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. / Aapro, Matti S.; Alberts, David S; Salmon, Sydney E.

In: Cancer Chemotherapy and Pharmacology, Vol. 10, No. 3, 1983, p. 161-166.

Research output: Contribution to journalArticle

@article{09e11a1d22f741f9b9915e5b666de27a,
title = "Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay",
abstract = "Purified human leukocyte interferon produced by recombinant techniques (IFN-αA) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-αA. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-αA and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-αA is due to some of their common mechanisms of action.",
author = "Aapro, {Matti S.} and Alberts, {David S} and Salmon, {Sydney E.}",
year = "1983",
doi = "10.1007/BF00255753",
language = "English (US)",
volume = "10",
pages = "161--166",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay

AU - Aapro, Matti S.

AU - Alberts, David S

AU - Salmon, Sydney E.

PY - 1983

Y1 - 1983

N2 - Purified human leukocyte interferon produced by recombinant techniques (IFN-αA) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-αA. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-αA and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-αA is due to some of their common mechanisms of action.

AB - Purified human leukocyte interferon produced by recombinant techniques (IFN-αA) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-αA. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-αA and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-αA is due to some of their common mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=0020635925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020635925&partnerID=8YFLogxK

U2 - 10.1007/BF00255753

DO - 10.1007/BF00255753

M3 - Article

C2 - 6861260

AN - SCOPUS:0020635925

VL - 10

SP - 161

EP - 166

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -